Trial Profile
Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Chronic myeloid leukaemia; Chronic neutrophilic leukaemia; Leukaemia
- Focus Therapeutic Use
- 24 Feb 2020 Status changed from recruiting to completed.
- 27 Dec 2019 Results (data cut off: 17 October 2018) assessing safety and efficacy of single-agent ruxolitinib in patients with CNL or aCNL published in the Journal of Clinical Oncology
- 04 Dec 2018 Results (n=40; data cut-off October 2017) assessing efficacy of ruxolitinib in chronic neutrophilic leukemia or atypical chronic myeloid leukemia patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.